Navigation Links
Incidence of Gastrointestinal Disorders in Patients With Parkinson's Disease Increased Over Time and Impacted Clinical and Health Economic Outcomes
Date:6/14/2011

BRUSSELS, June 14, 2011 /PRNewswire/ -- A new study investigating the incidence and impact of gastrointestinal disorders (GID) among patients with Parkinson's disease (PD) found that patients who received both a PD diagnosis and a prior GID diagnosis appeared to have worse health outcomes compared to patients who received a diagnosis for PD with no prior GID diagnosis.  This retrospective observational analysis of US administrative health claims data was published this month in the Journal of Parkinson's Disease.  

The study concluded that the majority of people diagnosed with PD acquired at least one GID, with incidence reaching 65% of patients four years after diagnosis.  In addition, PD patients with pre-existing GIDs before PD diagnosis were more likely to develop neurological, movement and urinary disorders, and may have required a higher level of healthcare utilization and increased healthcare costs.  

"This analysis reinforced the clinical impact of gastrointestinal disorders among people living with Parkinson's disease," commented study author, Dr. Florent Richy, Head of Global Epidemiology, UCB and Adjunct Professor of Epidemiology at the University of Liege, Belgium. "These patients tended to have worse health outcomes and required a higher level of care overall."

GIDs – such as difficulty in swallowing (dysphagia), delayed gastric emptying (gastroparesis) and bowel dysfunction – are the more commonly observed non-motor symptoms of PD.  GIDs affect nearly all aspects of the gastrointestinal system, and tend to worsen as PD progresses.  

Study Findings

Increased incidence over time of GIDs in patients diagnosed with PD

  • 29% of patients diagnosed with PD had been diagnosed with GIDs in the previous year
  • After four years, the proportion of PD patients diagnosed with GIDs increased to:
    • 50% for patients younger than 65 years of age
    • 68% for patients between 65 and 75 years of age
    • 72% for patients older than 75 years of age

PD patients with prior GID diagnosis experienced higher incidences of the following, according to a subset analysis

  • Dysfunctions of the neuropsychiatric, autonomic and sensory systems
    • Depression – 1.23-fold higher in PD patients with GIDs (p=0.0347)
    • Anxiety – 1.61-fold higher in PD patients with GIDs (p=0.0062)
    • Psychosexual dysfunction – 8.00-fold higher in PD patients with GIDs (p=0.0499)
    • Ataxia – 1.24-fold higher in PD patients with GIDs (p=0.0286)
    • Pain – 1.29-fold higher in PD patients with GIDs (p=0.0003)
  • Motor, urogenital, and cardiovascular disturbances
    • Movement disorders – 1.39-fold higher in PD patients with GIDs (p=0.0053)
    • Urinary incontinence – 1.43-fold higher in PD patients with GIDs (p=0.0156)
    • Falls – 1.44-fold higher in PD patients with GIDs (p=0.0356)
  • Increased healthcare utilization and costs
  • ER visits – 1.42-fold higher in PD patients with GIDs (p=0.0011)
  • Drugs prescribed for pain, sleep disorders or depression – 1.06-fold higher in PD patients with GIDs (p=0.0432)
  • PD-related healthcare costs – 1.13-fold higher in PD patients with GIDs (p=0.0038)
  • Non-PD-related healthcare costs – 1.12-fold higher in PD patients with GIDs (p=0.0088)

About the Study

The objectives of this retrospective observational study were to examine the incidence of GID in PD patients in a US population, and to examine subsequent PD-related outcomes in patients with GIDs.  Findings came from a U.S. health claims database* of patients with PD who had at least one claim between January 2000 and December 2008 that was associated with a PD diagnosis.  In a subset of continuously treated patients, 485 patients with PD and GID diagnosis up to six months before their PD diagnosis were matched to 485 controls with PD but no prior GID diagnosis six months before their PD diagnosis.  These patients had at least two claims that were associated with a PD diagnosis, and were continuously treated with levodopa and/or a dopamine agonist during the two year follow-up period.  

* Data Source: IMS LifeLink: Health Plan Claims Database, PharMetrics, Inc., a unit of IMS Health, Watertown, WA.  ©2009, All Rights Reserved.

The IMS  LifeLink Health Plan Claims Database includes longitudinal, integrated, patient-level medical and pharmaceutical claims comprising five billion patient observations from across the United States comprised of over 70 million patients from over 100 health plans, including medical services and prescription drug information across the entire continuum of care.

For further information
Andrea Levin, Senior Manager, Communications & PR, CNS, UCB, Inc.
T +1  770.970.8352 / Mobile: +1 404.483.7329  andrea.levin@ucb.com

Nancy Nackaerts, External Communications, UCB
T +32.473.864.414, nancy.nackaerts@ucb.com

Eimear O Brien, Associate Director, Global CNS Communications
T +32 2 559 9271, eimear.obrien@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8,500 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2010. UCB is listed on Euronext Brussels (symbol: UCB).

Forward-looking statements

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of its employees.


'/>"/>
SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
2. BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients
3. New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients
4. Dronedarone (Multaq(R)) Reduced the Incidence and Duration of Hospitalization in Patients with Atrial Fibrillation
5. AMT: Glybera(R) Lowers Pancreatitis Incidence Significantly
6. Study Finds Family History, Higher Incidence of Sunburns Associated With Rosacea
7. Mayo Clinic: Retired National Football League Linemen Have High Incidence of Sleep Apnea
8. Horizon Therapeutics HZT-501 Significantly Reduces Incidence of NSAID-Induced Upper Gastrointestinal Ulcers in Patients With Mild-to-Moderate Pain
9. Patients Taking VIMOVO(TM) Showed a Decrease in Incidence of NSAID-Associated Ulcers
10. Daily Intake of Yakult Is Efficacious in Reducing Incidence of Acute Diarrhea in Young Children
11. Phase 2b Data Suggest ReVisions Oral Fenretinide (RT-101) Slows Lesion Growth, Preserves Vision and Reduces Incidence of Neovascularization in Geographic Atrophy Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, Inc., ... development and manufacturing of collagen and mineral based ... today that Bill Messer has joined ... to further leverage the growing portfolio of oral ... Bill joins the Collagen Matrix executive ...
(Date:6/24/2016)... June 24, 2016 ... announced the addition of the " Global Markets ... This report focuses ... an updated review, including its applications in various applications. ... market, which includes three main industries: pharmaceutical and biotechnology, ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
(Date:6/24/2016)... ... 24, 2016 , ... People across the U.S. are sharpening their pencils and ... essay contest in which patients and their families pay tribute to a genetic counselor ... National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):